Skip links

Technology

Technology Background

A Targeted, Tailored and Sustained Drug Treatment

Targeted

Targeted

Significantly Increases bioavailability by 10-20x as compared to eye drops

Tailored

Tailored

Ability to deliver multiple drugs to the eye via the Contact Lens

Drug Range

Drug Range

Both hydrophobic and hydrophilic with a molecular weight of 70 – 1500 & concentration of 20 to 50 mg/ml

Sustained

Sustained

Delivers drugs consistently for extended durations - no need for multiple daily eye drop instillations. Release rates increased and decreased by Vitamin E concentration

Commercial and Safe Raw Materials

Commercial and Safe Raw Materials

Approved Bandage Contact Lens (Senofilcon A), USP Drugs, USP Vitamin E, Preservative-Free, 0.5% Polyvinylpyrrolidone

Freya Technology Platform

Providing Significant Improvements over Yesterday’s Eye Drop Technology

Provides Unique
Sustained Release

Continuous
Therapeutic Dose

Removes Compliance
& Instillation Issues

Technology Applications

$1.5B Markets

FDA Approved Senofilcon A Contact Lens

FDA Approved Drugs

Indication

Infection

Glaucoma

Ocular Cystinosis

Post Ocular Surgery

Corneal Defects

Rare Diseases/Myopia Control